Trial Profile
A Pilot Study of Adjuvant Therapy of Gefitinib (Iressa, ZD1839) in Patients With Resectable Hepatocellular Carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary)
- Indications Liver cancer
- Focus Biomarker; Therapeutic Use
- 11 Apr 2019 Planned End Date changed from 1 Dec 2012 to 1 Sep 2019.
- 11 Apr 2019 Planned End Date changed from 1 Dec 2012 to 1 Sep 2019.
- 11 Apr 2019 Status changed from completed to active, no longer recruiting.